Maximum quantity allowed is 999
CAS RN: 129-06-6 | Product Number: W0005
Warfarin Sodium (contains Isopropyl Alcohol)
Purity: >98.0%(HPLC)
- 3-(α-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt (contains Isopropyl Alcohol)
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt (contains Isopropyl Alcohol)
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 5G |
$52.00
|
5 | 4 | ≥20 |
|
| 25G |
$155.00
|
2 | 1 | 10 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | W0005 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__1__9H__1__5NaO__4 = 330.31 |
| Physical State (20 deg.C) | Solid |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive |
| CAS RN | 129-06-6 |
| Related CAS RN | 81-81-2 |
| Reaxys Registry Number | 5469050 |
| PubChem Substance ID | 87560363 |
| Merck Index (14) | 10038 |
| MDL Number | MFCD00083223 |
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 91.0 % |
| 2-Propanol | 7.0 to 9.0 % |
| Solubility in water | Completely soluble |
| Solubility (very soluble in) | Alcohol |
| Solubility (slightly sol. in) | Ether,Chloroform |
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H300 : Fatal if swallowed. H360 : May damage fertility or the unborn child. H370 : Causes damage to organs. H372 : Causes damage to organs through prolonged or repeated exposure. H373 : May cause damage to organs through prolonged or repeated exposure. H412 : Harmful to aquatic life with long lasting effects. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P307 + P311 : IF exposed: Call a POISON CENTER or doctor/ physician. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
| RTECS# | GN4725000 |
| UN Number (DOT-AIR) | UN1544 |
| Class (DOT-AIR) | 6.1 |
| Packing Group (TCI-A) | II |
| HS Number | 2932.20.4500 |
Warfarin is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site I on HSA. Those were confirmed using our warfarin sodium with Surface Plasmon Resonance (SPR) and a method using fluorescent probes. 【SPR】Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.
Fluorescent Dye Cocktail for Multiplex Drug￢Site Mapping on Human Serum Albumin
J. C. Er, M. Vendrell, M. K. Tang, D. Zhai, Y. T. Chang, ACS Comb. Sci. 2013, 15, 452.
High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE
R. L. Rich, Y. S. Day, T. A. Morton , D. G. Myszka, Anal Biochem. 2001, 296, 197.
Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels
Characterizing a drug's primary binding site on albumin
Y. S. Day, D. G. Myszka, J. Pharm. Sci. 2003, 92, 333.
Structural basis of the drug-binding specificity of human serum albumin
Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol
M. Ufer, Clin. Pharmacokinet. 2005, 44, 1227.
Systematic overview of warfarin and its drug and food interactions
Pharmacogenetics of warfarin elimination and its clinical implications
H. Takahashi, H. Echizen, Clin. Pharmacokinet. 2001, 40, 587.
Pharmacogenetics of warfarin: current status and future challenges
M. Wadelius, M. Pirmohamed, Pharmacogenomics J. 2007, 7, 99.
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
B. F. Gage, L. J. Lesko, J. Thromb. Thrombolysis. 2008, 25, 45.
Articles/Brochures
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.